Recently, GuoKe Ion, a company specializing in integrated solutions for ion therapy and wellness, proudly announced the successful closure of its inaugural equity financing round, raising a substantial RMB 800 million. This funding was jointly spearheaded by the Zhongguancun Independent Innovation Special Fund, part of the National Social Security Fund and managed by Legend Capital, alongside Legend Capital itself. Since its inception in April 2018, GuoKe Ion has harnessed the formidable research prowess of the Institute of Modern Physics, affiliated with the Chinese Academy of Sciences. In a landmark achievement in 2019, the company unveiled China's pioneering carbon ion therapy system, boasting independent intellectual property rights, which promptly entered clinical trials the subsequent year.

Following six years of relentless technological refinement, GuoKe Ion's product suite has evolved into a sophisticated multi-ion combined therapy system. This positions it as the sole domestic entity capable of autonomously supplying a comprehensive array of ion therapy hardware and software solutions. With an impressive order volume that places it at the forefront of the industry, four of its cutting-edge devices have already been deployed in clinical settings, garnering widespread acclaim.

Recently, the company has marked another milestone by successfully developing the world's inaugural light ion combined therapy device, a breakthrough that promises to further slash treatment expenses. GuoKe Ion has articulated its vision for utilizing this latest round of financing to bolster its core technological capabilities, expand its global footprint, enhance its corporate governance framework, and construct an all-encompassing platform dedicated to precision ion radiotherapy.